Vigil Neuroscience, Inc. (VIGL) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Ivana Magovcevic-Liebisch	President, Chief Executive Officer & Director	940,700	1967
David Gray	Chief Scientific Officer	601,566	1975
Jennifer Ziolkowski	Chief Financial Officer	650,888	1975
Petra Kaufmann	Chief Medical Officer	665,897	1966
Eric Brophy	Senior Manager of Information Technology	0	N/A
Kevin Durfee	Vice President & Head of Information Technology	0	N/A
Charles J. Democko	Senior Vice President, Regulatory Affairs & Quality	0	1955
Evan A. Thackaberry	Senior Vice President & Head of Early Development	0	1973
April Effort	Vice President & Head of Corporate Development	0	N/A
Leah Gibson	Vice President of Investor Relations and Corporate Communications	0	N/A
Sharon Morani	Senior Director of Facilities & Operations	0	N/A
Weeteck Yeo	Senior Vice President of Strategic Operations	0	N/A
Christian Mirescu	Senior Vice President & Head of Neuroimmunology	0	N/A
Ommer Chohan	Secretary	0	N/A

Name

Title

Pay

Year Born

Ivana Magovcevic-Liebisch

President, Chief Executive Officer & Director

940,700

1967

David Gray

Chief Scientific Officer

601,566

1975

Jennifer Ziolkowski

Chief Financial Officer

650,888

1975

Petra Kaufmann

Chief Medical Officer

665,897

1966

Eric Brophy

Senior Manager of Information Technology

N/A

Kevin Durfee

Vice President & Head of Information Technology

N/A

Charles J. Democko

Senior Vice President, Regulatory Affairs & Quality

1955

Evan A. Thackaberry

Senior Vice President & Head of Early Development

1973

April Effort

Vice President & Head of Corporate Development

N/A

Leah Gibson

Vice President of Investor Relations and Corporate Communications

N/A

Sharon Morani

Senior Director of Facilities & Operations

N/A

Weeteck Yeo

Senior Vice President of Strategic Operations

N/A

Christian Mirescu

Senior Vice President & Head of Neuroimmunology

N/A

Ommer Chohan

Secretary

N/A

Description

Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.